Company: HMDCF
Filing Date: 2025-06-30
Form Type: 6-K
Source: 0001648257-25-000047
Chunk: 0

Company: HUTCHMED (China) Ltd
Filing Date: 2025-06-30
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the Month of June2025

Commission File Number: 001-37710

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ⌧ Form 40-F ◻</div>

HUTCHMED (CHINA) LIMITED Form 6-K EXHIBIT INDEX

| Exhibit No.  |   | Description                                                                                                                                                                                                                      |
| ​            | ​ | ​                                                                                                                                                                                                                                |
| Exhibit 99.1 | ​ | Announcement relating to blocklisting six monthly return                                                                                                                                                                         |
| ​            | ​ | ​                                                                                                                                                                                                                                |
| Exhibit 99.2 | ​ | Announcement relating to total voting rights                                                                                                                                                                                     |
| ​            | ​ | ​                                                                                                                                                                                                                                |
| Exhibit 99.3 | ​ | Announcement relating to HUTCHMED announcing China approval for ORPATHYS® in combination with TAGRISSO® for the treatment of lung cancer patients with MET amplification after progression on first-line EGFR inhibitor therapy​ |

2

SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| ​ | HUTCHMED (CHINA) LIMITED |                         |
| ​ | ​                        | ​                       |
| ​ | ​                        | ​                       |
| ​ | By:                      | /s/ Johnny Cheng        |
| ​ | Name:                    | Johnny Cheng            |
| ​ | Title:                   | Chief Financial Officer |

Date: June 30, 2025

3